(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(1.30%) $1.948
(-0.16%) $2 343.50
(0.13%) $27.57
(0.76%) $929.10
(-0.34%) $0.932
(-0.46%) $10.97
(-0.42%) $0.797
(0.25%) $92.11
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.29%
@ $374.79
発行日: 26 4月 2024 @ 23:35
リターン: -0.53%
前回のシグナル: 4月 26 - 04:51
前回のシグナル:
リターン: 1.05 %
Live Chart Being Loaded With Signals
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France...
Stats | |
---|---|
本日の出来高 | 228 781 |
平均出来高 | 288 858 |
時価総額 | 22.16B |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $-0.710 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -72.53 |
ATR14 | $8.87 (2.38%) |
ボリューム 相関
argenx SE 相関
10 最も負の相関 | |
---|---|
FFBW | -0.915 |
HALL | -0.903 |
HTBI | -0.895 |
SATS | -0.893 |
LKFN | -0.888 |
IBEX | -0.886 |
OBT | -0.886 |
HSII | -0.882 |
VC | -0.88 |
SIDU | -0.878 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
argenx SE 相関 - 通貨/商品
argenx SE 財務諸表
Annual | 2023 |
収益: | $1.23B |
総利益: | $1.11B (90.39 %) |
EPS: | $-5.16 |
FY | 2023 |
収益: | $1.23B |
総利益: | $1.11B (90.39 %) |
EPS: | $-5.16 |
FY | 2022 |
収益: | $410.75M |
総利益: | $381.32M (92.83 %) |
EPS: | $-13.05 |
FY | 2021 |
収益: | $497.28M |
総利益: | $0.00 (0.00 %) |
EPS: | $-7.99 |
Financial Reports:
No articles found.
argenx SE
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。